There is a proposed association that exists between attention-deficit disorders and chronic pain conditions. This case represents an interesting phenomenon previously reported in the literature, specifically, the improvement in fibromyalgia symptoms with treatment of comorbid ADHD. While atomoxetine is not the standard treatment for fibromyalgia, our case report suggests the potential dual treatment effects of this nonstimulant medication which warrants further research. This report aims to provide further evidence regarding the consideration of atomoxetine in alleviating ADHD-related symptoms and fibromyalgia-associated pain and cognitive impairments. 

This case report suggests that atomoxetine may be a promising adjunct treatment for patients with comorbid ADHD and fibromyalgia. Further research to understand the potential mechanism of action of atomoxetine in targeting both disorders could have profound implications for the treatment of comorbid conditions involving chronic pain and cognitive deficits.